Immuron (IMRN) Depreciation & Amortization (CF) (2020 - 2021)
Immuron's quarterly Depreciation & Amortization (CF) came in at $33622.1 in Q2 2021, up 16.44% year-on-year from $28875.2 in Q2 2020, and up 16.44% quarter-over-quarter from $28875.2 in Q2 2020.
Immuron has reported Depreciation & Amortization (CF) for 2 years, with the latest figure at $33622.1 in Q2 2021.
- For the quarter ending Q2 2021, Depreciation & Amortization (CF) rose 16.44% year-over-year to $33622.1; the trailing twelve-month figure through Aug 2022 stood at $33622.1 (changed N/A YoY), and the FY2025 full-year result was $32204.2, up 6.79% from the prior year.
- Depreciation & Amortization (CF) for Q2 2021 stood at $33622.1, up from $28875.2 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $33622.1 in Q2 2021, with the low at $28875.2 in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 33,622.15 |
| Jun 30, 2021 | 33,622.15 |
| Jun 30, 2020 | 28,875.21 |
| Jun 30, 2020 | 28,875.21 |